[1] Y, Xie. (2017). Hepatitis B virus-associated hepatocellular carcinoma. Advances in experimental medicine and biology. [2] Jiang, Y., Han, Q., Zhao, H., Zhang, J. (2021, May 20). The mechanisms of HBV-induced hepatocellular carcinoma. Journal of hepatocellular carcinoma. [3] Liver cancer statistics: World cancer research fund international. WCRF International. (2022, April 14). [4] Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. (2017). Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. [5] Du Sunda, et al. SCG101 TCR-T Cell Therapy Achieves Rapid and Sustained HBsAg Reduction with >40% HBsAg Loss in HBV-Related Hepatocellular Carcinoma Patients. AASLD 2024 No. 5026[6] https://www.scgcell.com/newsinfo/6555471.html
